Conformingly, our previous study has demonstrated NKG2D expressions of CD56+ NK cells were decreased in untreated RR-MS patients in comparison with patient group treated with IFN-β and also revealed the elevation in treated group was negatively correlated with their expanded disability status scale (EDSS) scores (189). The gene discussed is KLRK1; the disease is myeloid sarcoma.